ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

ADMA Biologics (NASDAQ:ADMA) announced its earnings results on Wednesday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03, FiscalAI reports. The company had revenue of $141.10 million during the quarter, compared to analyst estimates of $138.11 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.15 earnings per share.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV drove growth: Revenue rose 31% year over year to $124.7 million, with management citing broader physician adoption, new patient starts, and continued pull-through. The company said primary immunodeficiency remains the main growth driver, while uptake in secondary immunodeficiency has been more moderate.
• Profitability and outlook improved: Gross margin reached 71%, and adjusted EBITDA grew 32% year over year to $77.3 million. ADMA maintained its 2026 revenue outlook of at least $530 million while raising minimum adjusted EBITDA guidance to $275 million and adjusted net income guidance to $180 million.
• BIVIGAM remained under pressure: Revenue fell to $15.4 million from $19.4 million in the second quarter and $23.8 million a year earlier, amid pricing and channel competition. Management noted signs of utilization stabilization entering the fourth quarter but said discounting pressures persist.
• Share repurchases continued at scale: ADMA repurchased $181.4 million of stock in the first nine months, buying back 16.5 million shares, or about 6.3% of year-end 2025 shares outstanding. The company reiterated its target of at least $200 million in repurchases for 2026.
• SG-001 advanced, but timing remains uncertain: The FDA provided constructive pre-IND feedback on the candidate’s proposed clinical strategy and assay, and ADMA plans to incorporate recommendations into its IND preparations. Management did not provide a filing timeline and expects higher fourth-quarter R&D spending as it produces conformance lots.

ADMA Biologics Trading Down 5.7%

NASDAQ ADMA traded down $0.63 during trading hours on Wednesday, hitting $10.48. 13,368,485 shares of the company were exchanged, compared to its average volume of 2,851,409. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $10.07 and a 200 day moving average price of $10.93. The stock has a market cap of $2.35 billion, a PE ratio of 14.97 and a beta of 0.65.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Mizuho lowered their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, ADMA Biologics has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus, while GAAP EPS was $0.22 and adjusted EPS was $0.23—both above estimates. GAAP net income rose 37% year over year to $49.9 million. ADMA Q3 results and business update
• Positive Sentiment: ASCENIV revenue increased 31% year over year to $124.7 million. Gross margin expanded by about 1,450 basis points to 71%, and adjusted EBITDA grew 32% to $77.3 million, indicating improving profitability and operating leverage. ADMA Q3 results and business update
• Positive Sentiment: The company increased its adjusted earnings outlook, cited encouraging regulatory feedback for SG-001, and highlighted share repurchases and evidence supporting ASCENIV’s commercial position. ADMA Q3 results and business update
• Neutral Sentiment: ADMA reiterated its FY2026 revenue guidance rather than raising it. Revenue grew 5% year over year, a more modest rate than ASCENIV’s growth; these factors may have tempered the upbeat earnings report, though the provided articles do not establish why the stock fell. ADMA Q3 results and business update

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.